Remdesivir versus usual care in the treatment of patients with COVID-19
Remdesivir was approved by the Food and Drug Administration in 2020 for treating hospitalized COVID-19 patients and those at high risk of severe disease. Although studies have shown a reduced risk of severe outcomes during the Omicron era compared to earlier variants, data on the effectiveness of remdesivir during...